{
  "content": "†\nThe hazard ratios compare amiodarone with no amiodarone.\n‡\nCauses of death are classified as CV, non-CV, and unknown cause.\nDiscussion",
  "source": "https://www.jacc.org/doi/10.1016/j.jacc.2014.07.967",
  "chunk_id": "fea4ddae-0c5c-48a7-92cd-24f45fb80b9a",
  "similarity_score": 0.39208102226257324,
  "query": "amiodarone beta-blockers mortality death cardiovascular outcomes hazard ratio odds ratio",
  "rank": 16,
  "title": "Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial",
  "authors": "Greg Flaker, Renato D. Lopes, Elaine Hylek, Daniel M. Wojdyla, Laine Thomas, Sana M. Al-Khatib, Renee M. Sullivan, Stefan H. Hohnloser, David Garcia, Michael Hanna, John Amerena, Veli-Pekka Harjola, Paul Dorian, Alvaro Avezum, Matyas Keltai, Lars Wallentin, Christopher B. Granger",
  "year": "2014",
  "journal": "JACC",
  "reference": "Flaker, G., Lopes, R. D., Hylek, E., Wojdyla, D. M., Thomas, L., Al-Khatib, S. M., Sullivan, R. M., Hohnloser, S. H., Garcia, D., Hanna, M., Amerena, J., Harjola, V.-P., Dorian, P., Avezum, A., Keltai, M., Wallentin, L., & Granger, C. B. (2014). Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: Insights from the ARISTOTLE trial. JACC, 64(15), 556-575. Not available.",
  "doi": "Not available",
  "chunk_index": 59,
  "total_chunks": 111,
  "retrieved_at": "2025-07-24T22:33:23.680749"
}